C4's Andrew Hirsch blows up IPO to $182M, while oncolytic virus upstart nabs $87M offering
On Friday, Massachusetts-based biotechs C4 Therapeutics and Oncorus became the latest to jump onto Nasdaq.
Less than a month after being tapped as C4 Therapeutics’ new CEO, Bind and Agios vet Andrew Hirsch is marching the biotech to Wall Street with an upsized IPO.
C4, which initially filed for $100 million, priced 9.6 million shares at $19 million apiece, netting $182.4 million. The proceeds will be used to push the company’s first protein degradation candidates into the clinic, according to an S-1/A filing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.